Drug Profile
D-galactose - Orpha Labs
Alternative Names: ORL-1GLatest Information Update: 23 Feb 2022
Price :
$50
*
At a glance
- Originator Orpha Labs
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Lysosomal storage diseases
Most Recent Events
- 23 Feb 2022 No development reported - Phase-I/II for Lysosomal storage diseases (In adolescents, In children, In infants, In neonates, In adults) in Turkey (PO) (NCT03404856)
- 31 Oct 2019 Orpha Labs completes a phase I/II trial in Lysosomal storage diseases (In neonates, In infants, In children, In adolescents, In adults) in Turkey (PO) (NCT03404856)
- 31 Oct 2017 Phase-I/II clinical trials in Lysosomal storage diseases (In neonates, In infants, In children, In adolescents, In adults) in Turkey (PO) (NCT03404856)